Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection
Yıl: 2021 Cilt: 38 Sayı: 2 Sayfa Aralığı: 141 - 142 Metin Dili: İngilizce DOI: 10.4274/balkanmedj.galenos.2020.2020.9.106 İndeks Tarihi: 13-05-2021
Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection
Öz: -
Anahtar Kelime: Belge Türü: Makale Makale Türü: Editöre Mektup Erişim Türü: Erişime Açık
- 1. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147. [Crossref]
- 2. Stephens DM, Spurgeon SE. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol. 2015;6(5):242-252. [Crossref]
- 3. Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5(48):eabd0110. [Crossref]
- 4. Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26(2):e233-e240. [Crossref]
| APA | Hindilerden F, Yonal-Hindilerden I, Diz-Kucukkaya R (2021). Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection. , 141 - 142. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| Chicago | Hindilerden Fehmi,Yonal-Hindilerden Ipek,Diz-Kucukkaya Reyhan Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection. (2021): 141 - 142. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| MLA | Hindilerden Fehmi,Yonal-Hindilerden Ipek,Diz-Kucukkaya Reyhan Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection. , 2021, ss.141 - 142. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| AMA | Hindilerden F,Yonal-Hindilerden I,Diz-Kucukkaya R Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection. . 2021; 141 - 142. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| Vancouver | Hindilerden F,Yonal-Hindilerden I,Diz-Kucukkaya R Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection. . 2021; 141 - 142. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| IEEE | Hindilerden F,Yonal-Hindilerden I,Diz-Kucukkaya R "Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection." , ss.141 - 142, 2021. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| ISNAD | Hindilerden, Fehmi vd. "Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection". (2021), 141-142. https://doi.org/10.4274/balkanmedj.galenos.2020.2020.9.106 |
| APA | Hindilerden F, Yonal-Hindilerden I, Diz-Kucukkaya R (2021). Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection. Balkan Medical Journal, 38(2), 141 - 142. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| Chicago | Hindilerden Fehmi,Yonal-Hindilerden Ipek,Diz-Kucukkaya Reyhan Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection. Balkan Medical Journal 38, no.2 (2021): 141 - 142. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| MLA | Hindilerden Fehmi,Yonal-Hindilerden Ipek,Diz-Kucukkaya Reyhan Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection. Balkan Medical Journal, vol.38, no.2, 2021, ss.141 - 142. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| AMA | Hindilerden F,Yonal-Hindilerden I,Diz-Kucukkaya R Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection. Balkan Medical Journal. 2021; 38(2): 141 - 142. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| Vancouver | Hindilerden F,Yonal-Hindilerden I,Diz-Kucukkaya R Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection. Balkan Medical Journal. 2021; 38(2): 141 - 142. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| IEEE | Hindilerden F,Yonal-Hindilerden I,Diz-Kucukkaya R "Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection." Balkan Medical Journal, 38, ss.141 - 142, 2021. 10.4274/balkanmedj.galenos.2020.2020.9.106 |
| ISNAD | Hindilerden, Fehmi vd. "Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection". Balkan Medical Journal 38/2 (2021), 141-142. https://doi.org/10.4274/balkanmedj.galenos.2020.2020.9.106 |
